Autologous hematopoietic stem cell transplantation with low-intensity conditioning regimens in relapsing remitting multiple sclerosis: clinical outcomes and quality of life.

Description: The objective was to report the primary end point, which was the disability level defined by the EDSS score. Other studied end-points included safety, relapse-free survival (no acute relapses) and quality of life (QoL) changes.

Outcomes: A total of 258 patients with RRMS were enrolled in the study. There were no cases of transplantation-related mortality. The decrease of EDSS score from median 2.0 to 1.5 was observed at 12 months after AHSCT, and it remained at this level during the follow-up of more than 60 months. The EDSS score improved significantly for the entire group (P <0.001). AHSCT was accompanied by significant improvement in patient’s Quality of Life (QoL). Relapse free survival (RFS) was dramatically better in patients with EDSS<4 as compared to patients with EDSS=4-6.5. This finding supports the idea that AHSCT is beneficial for patients with highly active relapsing-remitting MS and moderate disability. Estimated RFS at the follow-up of 36 months was 95.6% at the follow-up of 60 months, 88.2%; at the follow-up of 84 months, 83.3%